The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,258 | -27,377 |
| Depreciation | 89 | 187 |
| Stock-based compensation expense | 1,384 | 3,048 |
| Amortization of right-of-use assets | 135 | 270 |
| Accretion of discounts on short-term investments, net | 252 | 438 |
| Accounts receivable and unbilled receivable | -272 | -247 |
| Prepaid expenses and other current assets | -1,080 | -388 |
| Other assets | 148 | 332 |
| Accounts payable and accrued liabilities | -1,961 | 3,223 |
| Operating lease liabilities | -175 | -338 |
| Net cash used in operating activities | -10,834 | -21,122 |
| Capital expenditures | 18 | 26 |
| Maturities of short-term investments | 19,519 | 35,020 |
| Purchases of short-term investments | 9,341 | 55,797 |
| Sales of short-term investments | 0 | 1,236 |
| Net cash provided by (used in) investing activities | 10,160 | -19,567 |
| Proceeds from exercise of options | 25 | 3 |
| Net cash provided by financing activities | 25 | 3 |
| Net change in cash and cash equivalents | -649 | -40,686 |
| Cash and cash equivalents at beginning of period | 51,470 | - |
| Cash and cash equivalents at end of period | 10,135 | - |
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)